Diagnosing the declining industry sponsorship in clinical research

Jianan Huang ()
Additional contact information
Jianan Huang: National Institute of Education, Nanyang Technological University

Scientometrics, 2024, vol. 129, issue 1, No 24, 663-679

Abstract: Abstract By many measures, industry sponsorship is a crucial and even irreplaceable funding source for clinical research. This study aims to analyze the engagement of industry sponsorship in clinical research, which has seen a notable decline, from 43.61% in 2000 to 24.68% in 2020. To anatomy the characteristics of industry sponsored clinical trials and to diagnose its recent decline, 435,561 original records from ClinicalTrials.gov are analyzed to revisit the ever-changing role of industry sponsorship in clinical research, as well as its profound and far-reaching impacts. While the percentage of industry sponsorship in clinical trials has been decreasing in general throughout the last two decades, it remains the majority of funding sources for clinical research in specific areas around the Pacific Rim, but excluding the U.S. and China. Against the traditional wisdom that connects industry sponsorship to the late phases of clinical trials, it is observed that industry sponsorship shares a higher percentage than public sponsorship in and only in phase 1 clinical trials. Most significantly, data-driven results reveal that industry sponsorship contributes less to epidemic diseases than to non-communicable diseases. Recognizing this universal dilemma in the whole sector, the complementary roles of external collaboration and open innovation should be addressed to help facilitate R&D (research & development) decisions and hence improve investment returns in late phase clinical research. Analysis results remind policy-makers as well as related industry stakeholders of the need to further motivate the engagement of industry sponsorship in epidemic clinical research, especially during the post pandemic period.

Keywords: Clinical trial; Research evaluation; R&D decision; Industry-Academia-Research Cooperation; Drug development; University sponsorship (search for similar items in EconPapers)
Date: 2024
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s11192-023-04887-z Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:scient:v:129:y:2024:i:1:d:10.1007_s11192-023-04887-z

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/11192

DOI: 10.1007/s11192-023-04887-z

Access Statistics for this article

Scientometrics is currently edited by Wolfgang Glänzel

More articles in Scientometrics from Springer, Akadémiai Kiadó
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().